<DOC>
	<DOCNO>NCT02039336</DOCNO>
	<brief_summary>This phase I/II multi-center open-label proof concept study , consist two part . Part A study design identify recommended phase 2 dose ( RP2D ) combination regimen dacomitinib plus PD-0325901 patient advance KRAS mutant ( KRASm ) colorectal cancer ( CRC ) , non-small cell lung cancer ( NSCLC ) , pancreatic cancer . Part B design perform randomize comparison combination dacomitinib PD-0325901 versus standard care therapy patient advance KRASm CRC , NSCLC , pancreatic cancer . It hypothesize combination strategy progression free survival patient KRASm CRC , NSCLC pancreatic cancer double .</brief_summary>
	<brief_title>Dacomitinib Plus PD-0325901 Advanced KRAS Mutant Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Histological cytological proof advance colorectal cancer ( CRC ) , nonsmall cell lung cancer ( NSCLC ) pancreatic cancer Written documentation KRAS ( exon 2 , 3 4 ) mutation At least 18 year age old Able willing give write informed consent WHO performance status 0 1 Symptomatic untreated leptomeningeal disease Symptomatic brain metastasis Impairment gastrointestinal function Uncontrolled infectious disease Left ventricular ejection fraction &lt; 50 % Retinal degenerative disease history uveitis , retinal vein occlusion retinal detachment Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>